NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...

Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

When NICE recommends a treatment as an option for use with managed access, NHS England will make it available according to the conditions in the managed access agreement. See section 4f of The ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. Not eligible? Contact the stakeholder organisation that most closely represents your interests and ...

Abbreviations: Exa-cel, exagamglogene autotemcel. The market share for exa‑cel is based on NICE estimates and is for illustrative purposes. A low market share is anticipated because a lengthy hospital ...

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...

A list of downloadable documents created during development.

The meeting will take place as a webinar via Zoom, a secure web conferencing tool. This meeting will run from 10:00am to 1:00pm, although timings may be subject to change. You will receive your ...